Intercept Pharma (ICPT) Gets a Buy Rating from RBC Capital
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Intercept Pharma (ICPT), with a price target of $146.00. The company’s shares closed last Monday at $84.68.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 9.9% and a 53.4% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.
Intercept Pharma has an analyst consensus of Strong Buy, with a price target consensus of $166.33, representing an 80.8% upside. In a report issued on February 20, B.Riley FBR also reiterated a Buy rating on the stock with a $158.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $125.00 and a one-year low of $56.76. Currently, Intercept Pharma has an average volume of 629.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.